Published on
Sep 22, 2026
FDA Balances Peptide Policy with Enforcement Against Unlawful Peptide Sellers
Over the past year, industry has had a front row seat as the Food and Drug Administration (“FDA” or the “Agency”) decides just how much leeway it wants to afford the manufacture, marketing, and sale of peptide products, and just where it wants to draw the …
Source:
JD Supra - California
-
Neutral
